New roles include finance and research & development department leaders

HAMPTON, Va., November 27, 2018 – ivWatch, a medical device and biosensor technology company specializing in continuous monitoring solutions for the early detection of intravenous (IV) infiltrations and extravasations, is pleased to announce two new additions to its executive leadership team with the appointments of Nikki Lowe as chief financial officer and Jaclyn Lautz, Ph.D. as vice president of research & development. These executive and senior leadership positions will strengthen the company’s focus on global growth and increase the pace of their biosensor platform development.

“We’re thrilled to have two talented senior executives join our mission to keep more patients safe from preventable medical harm,” said Gary Warren, president and CEO of ivWatch. “Nikki and Jaclyn both have perfectly suited skills and insights to jump in and build their strategies supporting our roadmap and continued investment in new health care innovations.”

Nikki Lowe, Chief Financial Officer

As a member of the company’s executive management team and a direct report to President and CEO Gary Warren, Lowe will have primary responsibility for planning, implementing, managing and controlling all financial-related activities of the company. This will include accounting, finance, forecasting, strategic planning and manufacturing financial analysis.

Lowe has successfully led diverse global accounting functions for multi-divisional companies. She has more than 10 years of executive leadership experience, which includes mergers and acquisitions, financial operations, investor relations and strategic planning reporting and analysis in software and consumer industries. Most recently, she served as an Executive Vice President of Finance for Perfect Commerce Holdings, a global sourcing and procurement software solutions company that she helped facilitate its sale to a UK public entity.

Prior to that role, Lowe served in various accounting and finance leadership roles at top companies in Newport News, Va. including Spiegel, Newport News and Shape FX brands and Ferguson Enterprises. A certified public and global management accountant, Lowe also held senior associate positions in her early career at KPMG and Clifton Gunderson after receiving a bachelor’s degree in accounting from the University of Illinois in Springfield.

Jaclyn Lautz Ph.D., Vice President, Research & Development

As a senior leader, Lautz will oversee all product development and innovation efforts for the company. Her role in this new position includes directing the engineering teams on the design and development of new products and working across departments to bring new products to the market. She will also report directly to Warren.

Lautz rejoins ivWatch from Pricewaterhouse Coopers (PwC) where she was an advisory manager in the pharmaceutical and life sciences operations practice. From 2014-2017, Lautz was ivWatch’s Director of Regulatory Affairs & Quality Assurance, where she was involved with nearly every department in the company from research and development to post-market surveillance. Previous career experiences include six years working as an engineering innovation fellow at Applied Research Associates, a scientific research and engineering company, a biomedical engineer at Semprus Biosciences and a software engineer at an orthopedic clinic.

Lautz has a Ph.D. in mechanical engineering & materials science from Duke University where she worked with industry partners, Siemens and Boston Scientific, on new medical devices and treatment strategies for urological diseases. She holds a B.S. in biomedical engineering from Boston University. Her work is published in several physics and medical journals.

To learn more about ivWatch leadership, visit

About ivWatch:
ivWatch, LLC is the leading medical device manufacturer and biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is focused on our company vision of eliminating patient harm caused by infiltrations and extravasations. Through our innovative monitored IV solutions, we help minimize the risks associated with adverse IV events. Follow us on Twitter @ivWatch or Facebook @ivWatchLLC.


Amara Betoney,, Direct (757) 224-2606, Office (855) 489-2824 x7007, Mobile (757) 660-4949

ivWatch Logo White

Download Our Whitepaper

Thank you for requesting more information about the ivWatch Clinical Studies. The ivWatch Model 400 is the only continuous monitoring device for the early detection of IV infiltration and extravasation events.

[fc id='6'][/fc]

You have Successfully Subscribed!

Pin It on Pinterest